文献速递糖尿病肥胖与代谢综合征

2型糖尿病合并肥胖患者代谢/减重手术与药物/生活方式干预后健康相关生活质量与健康效用的比较:ARMMS-T2D研究

Health-Related Quality of Life and Health Utility After Metabolic/Bariatric Surgery Versus Medical/Lifestyle Intervention in Individuals With Type 2 Diabetes and Obesity: The ARMMS-T2D Study.
PubMed 文献 · Diabetes Care · 2025-01-01

ARMMS-T2D研究纳入228例2型糖尿病合并肥胖患者,随机分配至代谢/减重手术组(n=152)或药物/生活方式干预组(n=76),每年测量健康相关生活质量(SF-36)和健康效用(SF-6D)至12年。结果显示手术组在躯体成分评分、总体健康、躯体功能、活力和健康效用方面均优于药物/生活方式组,而心理成分评分两组无显著差异。

要点

  • 代谢/减重手术组12年躯体成分评分改善显著优于药物/生活方式组(+2.37 vs -0.95,差值3.32,P<0.001)。
  • 代谢/减重手术组健康效用改善优于药物/生活方式组(+0.02 vs -0.01,差值0.03,P=0.003)。
  • 心理成分评分两组变化均较小且无显著差异(-0.21 vs -0.89,差值0.68,P=0.48)。

主要发现

  • 基线平均±标准差年龄49.2±8.0岁,女性占68.4%,BMI 36.3±3.4 kg/m2,HbA1c 8.7±1.6%。
  • 12年间躯体成分评分在代谢/减重手术组改善显著大于药物/生活方式组(+2.37±0.53 vs -0.95±0.73;差值3.32±0.85;P<0.001)。
  • 代谢/减重手术与更好的总体健康(P<0.001)、躯体功能(P=0.001)和活力(P=0.003)相关。
  • 代谢/减重手术组BMI下降大于药物/生活方式组(P<0.001),且与躯体成分评分改善相关(r=-0.43;P<0.001)。
  • 躯体成分评分变化与HbA1c变化无关;心理成分评分自基线变化极小,两组随访期间相似(-0.21±0.61 vs -0.89±0.84;差值0.68±0.97;P=0.48);12年间健康效用改善在代谢/减重手术组大于药物/生活方式组(+0.02±0.01 vs -0.01±0.01;差值0.03±0.01;P=0.003)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Type 2 diabetes and obesity are associated with reduced health-related quality of life (HRQoL) and health utility (HU), but long-term effects of metabolic/bariatric surgery (MBS) compared with those of medical/lifestyle intervention (MLI) on these outcomes are unclear. RESEARCH DESIGN AND METHODS: We studied 228 individuals with type 2 diabetes and obesity randomly assigned to MBS (Roux-en-Y gastric bypass, sleeve gastrectomy, or gastric band; n = 152) or MLI (n = 76) in the ARMMS-T2D study. HRQoL (36-Item Short-Form Health Survey [SF-36], including Physical Component Score [PCS] and Mental Component Score [MCS]) and HU (Short Form 6 Dimensions [SF-6D]) were measured annually up to 12 years. RESULTS: At baseline, participants' mean ± SD age was 49.2 ± 8.0 years, 68.4% were female, BMI was 36.3 ± 3.4 kg/m2, and HbA1c was 8.7 ± 1.6%. PCS improved significantly more in the MBS versus MLI group over 12 years (+2.37 ± 0.53 vs. -0.95 ± 0.73; difference 3.32 ± 0.85; P < 0.001). MBS was associated with better general health (P < 0.001), physical functioning (P = 0.001), and vitality (P = 0.003). Reduction in BMI was greater after MBS versus MLI (P < 0.001) and correlated with improved PCS (r = -0.43; P < 0.001). Change in PCS was not associated with change in HbA1c. MCS changed minimally from baseline and was similar between MBS and MLI groups during follow-up (-0.21 ± 0.61 vs. -0.89 ± 0.84; difference 0.68 ± 0.97; P = 0.48). Improvements in HU were greater in the MBS versus MLI group over 12 years (+0.02 ± 0.01 vs. -0.01 ± 0.01; difference 0.03 ± 0.01; P = 0.003). CONCLUSIONS: Metabolic surgery produces sustained weight loss and improves PCS, general health, physical functioning, vitality, and HU in individuals with type 2 diabetes and obesity compared with medical therapy up to 12 years after intervention.

来源:Diabetes Care,查看原文。版权归原作者所有。

引用

  1. Simonson DC, Gourash WF, Arterburn DE, et al. Health-Related Quality of Life and Health Utility After Metabolic/Bariatric Surgery Versus Medical/Lifestyle Intervention in Individuals With Type 2 Diabetes and Obesity: The ARMMS-T2D Study. Diabetes Care. 2025. PMID: 39903478. doi:10.2337/dc24-2046

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。